Trials
Search / Trial NCT00002691

Combination Chemotherapy in Treating Pediatric Patients With Stage III or IV Non-Hodgkin's Lymphoma

Launched by MEMORIAL SLOAN KETTERING CANCER CENTER · Jun 30, 2004

Apply for Trial

Trial Information

Current as of March 15, 2025

Completed

Keywords

Stage Iii Childhood Lymphoblastic Lymphoma Stage Iv Childhood Lymphoblastic Lymphoma Stage Iii Childhood Small Noncleaved Cell Lymphoma Stage Iii Childhood Large Cell Lymphoma Stage Iv Childhood Large Cell Lymphoma

ClinConnect Summary

OBJECTIVES: I. Assess the feasibility of treating all histologic subgroups of pediatric non-Hodgkin's lymphoma on one protocol, with the addition of asparaginase during the induction and consolidation phases for diffuse lymphoblastic lymphoma and T-cell, large noncleaved cell diffuse lymphoma. II. Assess whether intensification of cyclophosphamide during induction therapy will achieve a complete response rate of 95% in 1 to 1.5 months for all histologies. III. Assess whether achieving remission induction in 1 month, administering cytarabine/methotrexate by continuous infusion during consoli...

Gender

ALL

Eligibility criteria

  • • DISEASE CHARACTERISTICS: See General Eligibility Criteria
  • • PATIENT CHARACTERISTICS: See General Eligibility Criteria

Trial Officials

Tanya Trippett, MD

Study Chair

Memorial Sloan Kettering Cancer Center

About Memorial Sloan Kettering Cancer Center

Memorial Sloan Kettering Cancer Center (MSKCC) is a world-renowned institution dedicated to cancer treatment, research, and education. As a leading clinical trial sponsor, MSKCC focuses on advancing innovative cancer therapies through rigorous scientific investigation and collaboration. The center's multidisciplinary team of experts employs cutting-edge methodologies to design and conduct trials that aim to improve patient outcomes and enhance understanding of cancer biology. With a commitment to translating research findings into clinical practice, MSKCC plays a pivotal role in shaping the future of oncology care and ensuring that patients have access to the latest therapeutic advancements.

Locations

New York, New York, United States

People applied

Timeline

First submit

Trial launched

Trial updated

Estimated completion

Not reported

Discussion 0

Similar Trials